ATROPHIC VAGINITIS TREATMENT MARKET ANALYSIS

Atrophic Vaginitis Treatment Market, By Treatment Type (Hormone therapies, Non-hormonal therapies, Others), By Distribution Channel (Hospital pharmacies, Retail pharmacies, Online pharmacies), By Application (vaginal dryness, vaginal burning, others), By End User (Hospitals, Clinics, Home care settings), By Region (North America, Latin America, Europe, Asia Pacific, and Middle East & Africa)

Atrophic Vaginitis Treatment Recent Developments:

New product launches

Imvexxy: Imvexxy is a vaginal insert that contains estradiol, a type of estrogen hormone. It was approved by the FDA in 2018 for the treatment of moderate to severe vaginal atrophy due to menopause.
Bijuva: Bijuva is a combination hormone therapy that contains estradiol and progesterone. It was approved by the FDA in 2018 for the treatment of moderate to severe vasomotor symptoms associated with menopause and prevention of postmenopausal osteoporosis.
Revaree: Revaree is a non-hormonal vaginal moisturizer that was launched in 2018. It is designed to provide long-lasting relief from vaginal dryness and discomfort.

Figure 2. Global Atrophic Vaginitis Treatment Market Share (%), by Treatment Type , 2023

Acquisition and partnerships:

Pfizer\'s acquisition of AMAG Pharmaceuticals: In 2020, Pfizer acquired AMAG Pharmaceuticals, which had developed Intrarosa, a treatment for moderate to severe dyspareunia due to menopause. This acquisition strengthened Pfizer\'s position in the women\'s health market.
Duchesnay USA\'s partnership with Bonafide: In 2019, Duchesnay USA, a women\'s health company, entered into a partnership with Bonafide, a women\'s health startup, to distribute Bonafide\'s over-the-counter products for menopause symptoms. This partnership allowed Duchesnay USA to expand its product offerings and reach a wider audience.